Human Rotavirus Vaccine Market Report 2023 (Global Edition)

Global Human Rotavirus Vaccine Market Report 2023 talks about crucial market insights with the help of segments and sub-segments analysis. In this section, we reveal an in-depth analysis of the key factors influencing Human Rotavirus Vaccine Industry growth. Human Rotavirus Vaccine market has been segmented with the help of its Product, Application , and others. Human Rotavirus Vaccine market analysis helps to understand key industry segments, and their global, regional, and country-level insights. Furthermore, this analysis also provides information pertaining to segments that are going to be most lucrative in the near future and their expected growth rate and future market opportunities. The report also provides detailed insights into factors responsible for the positive or negative growth of each industry segment.

Report scope is customizable as we have a huge database of Human Rotavirus Vaccine industry. We can deliver an exclusive report Edition/Consultation as per your data requirements. Request for your Free Sample Pages.

Based on the Product, the market is segmented into rotarix, rotateq, rotavac, rotavin-m1, and lanzhou lamb. The rotarix segment accounted for the largest share in terms of products during the forecast period. Rotarix oral vaccine is a medicine increasingly used in the prevention of diarrhea due to rotavirus. It is given as a 3-dose oral regimen beginning at 6 weeks of age.

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Human Rotavirus Vaccine Industry. Request a Free Sample PDF!

Based on the Application, the market is segmented into hospitals & clinics, academic, and research, and others. Hospitals & clinics hold the largest share in terms of application. Some private healthcare facilities will be given free-of-cost vaccines to all infants at the age of six, 10, and 14 weeks in hospitals and clinics.

The above Graph is for representation purposes only. This chart does not depict actual Market share. Please purchase the Human Rotavirus Vaccine market report 2023 Edition by contacting our team.

North America accounted for relatively the largest share of the human rotavirus vaccine market. The growth of the human rotavirus vaccine market in North America is fuelled by some key factors including the high prevalence of gastroenteritis and rising expenditure on healthcare. In North America, the prevalence of G1P[8] is relatively high due to the higher efficiency of Rotarix against infection caused by G1P[8]. G1P[8] rotaviruses are causing diarrheal infections in humans all over the world. On the other hand, Asia pacific is expected to grow at the fastest growth rate during the forecast period, as the rapidly growing population, increasing burden of diarrheal diseases in children, and advancements in medical care procedures. In the Asia Pacific region, government initiatives have been taken, where the rotavirus vaccine should be included in all national immunization programs, particularly in countries with high rotavirus gastroenteritis (RVGE) rates.

Region-wise, the market is analyzed across: (In case you wish to acquire a specific region or any country data then please contact us)

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only. To learn more about geographical trends request the free sample pages. Contact US!

Major players involved in the market include Bharat Biotech, Serum Institute of India Pvt. Ltd., GlaxoSmithKline plc., Merck & Co., Inc., BIOVIRx Inc., Sanofi, Lanzhou Institute of Biologicals Products Co., Ltd. Among others.

News:

• Bharat Biotech's rotavirus vaccine received Prequalification from WHO

In August 2021, Bharat Biotech International Limited announced that Rotavac 5D, a variant of its Rotavac vaccine, has received Prequalification from the World Health Organization (WHO). Rotavac vaccine is used to prevent rotavirus which causes severe diarrhea and vomiting and is mostly found in children. This is an important step to further strengthen Bharat Biotech’s position to prevent infections that affect millions in the developing world.

• FDA Approved Fully Liquid Presentation of GSK’s Rotarix Vaccine to Prevent Gastroenteritis Caused by Rotavirus

In November 2022, GlaxoSmithKline announced that the US Food and Drug Administration (FDA) has approved an oral-dosing applicator presentation liquid formulation of Rotarix which prevents rotavirus gastroenteritis caused by G1 and non-G1 types (G3, G4 and G9) in infants. This new formulation was developed with the vision to make it more convenient for healthcare providers to prepare Rotarix by removing the need to reconstitute the vaccine dose at the point of time.

Top Companies Market Share in Human Rotavirus Vaccine Industry: (In no particular order of Rank)

• Bharat Biotech
• Serum Institute of India Pvt. Ltd.
• GlaxoSmithKline plc.
• Merck & Co.Inc.
• BIOVIRx Inc.
• Sanofi
• Lanzhou Institute of Biologicals Products Co.Ltd.
• Others
• Confidential Data
• Access The Paid Version
• Data Hidden

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables..